Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.

Journal of medicinal chemistry - 23 Jan 2014

Parajuli Bibek, Fishel Melissa L, Hurley Thomas D

Abstract excerpt

Aldehyde dehydrogenase enzymes irreversibly oxidize aldehydes generated from metabolism of amino acids, fatty acids, food, smoke, additives, and xenobiotic drugs. Cyclophosphamide is one such xenobiotic used in cancer therapies. Upon activation, cyclophosphamide forms an intermediate, aldophosphamide, which can be detoxified to carboxyphosphamide by aldehyde dehydrogenases (ALDH), especially ALDH1A1 and ALDH3A1....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase
Share to Benzimidazoles
Share to Crystallography, X-Ray

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Drug Screening Assays, Antitumor

Share to Drug Synergism

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 24387105
DOI: 10.1021/jm401508p
PMCID: PMC3988914

Genes

ALDH2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.PMID 24387105Read ↗

CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancerSemantic proximity Read ↗

A Selective Competitive Inhibitor of Aldehyde Dehydrogenase 1A3 Hinders Cancer Cell Growth, Invasiveness and Stemness In VitroSemantic proximity Read ↗

Discovery of Novel Aldo-Keto Reductase 1C3 Inhibitors as Chemotherapeutic Potentiators for Cancer Drug ResistanceSemantic proximity Read ↗

Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

ALDH1 Bio-activates Nifuroxazide to Eradicate ALDHHigh Melanoma-Initiating CellsSemantic proximity Read ↗

Discovery of the First‐in‐Class Inhibitors of Hypoxia Up‐Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast ActivationSemantic proximity Read ↗

Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells.Semantic proximity Read ↗

Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1.Semantic proximity Read ↗

Relevance of aldehydes in understanding gene-drug interactions and cancer subpopulationsSemantic proximity Read ↗

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.Semantic proximity Read ↗

Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4.Semantic proximity Read ↗

Metabolite profiling reveals a connection between aldehyde dehydrogenase 1A3 and GABA metabolism in breast cancer metastasisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.